Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alvogen history
Alvogen company history timeline
The odds were not in Wessman’s favour: the global economic crash had left him with an empty wallet and, by the time he left Actavis in 2008, the crisis had cost him a whopping $250m.
Alvogen has also ventured into the biosimilars space via its sister company Alvotech, which was founded by Wessman in 2013.
Since January 2016, the index for listed generic companies dropped by 57 percent, while the broader index by Standard & Poor’s grew by well over 20 percent in the same period.
Meanwhile, in June 2017, the US Supreme Court ruled biosimilar companies would be able to essentially launch products upon approval, by allowing companies to provide notice of the drug’s launch prior to the FDA’s final sign off.
However, projections suggest this figure could reach $36bn by 2022.
Rate Alvogen's efforts to communicate its history to employees.
Alvogen jobs
Do you work at Alvogen?
Does Alvogen communicate its history to new hires?
Alvogen competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Andrx Corp | 1992 | - | 1,680 | - |
| Med Immune Inc | 1988 | $1.7B | 5,000 | - |
| Vion Pharmaceuticals, Inc. | 1992 | - | 20 | - |
| Titan Pharmaceuticals | 1992 | $557,000 | 23 | - |
| Novavax | 1987 | $682.2M | 791 | 5 |
| Advaxis | 2002 | $250,000 | 35 | - |
| GlobeImmune | 1995 | $6.5M | 22 | - |
| Protein Sciences | 1983 | $23.9M | 150 | - |
| Regulus Therapeutics | 2007 | $10.0M | 25 | - |
| Par Pharmaceutical Inc | 2003 | $260.0M | 400 | - |
Alvogen history FAQs
Zippia gives an in-depth look into the details of Alvogen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alvogen. The employee data is based on information from people who have self-reported their past or current employments at Alvogen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alvogen. The data presented on this page does not represent the view of Alvogen and its employees or that of Zippia.
Alvogen may also be known as or be related to Alvogen, Alvogen Inc and Alvogen, Inc.